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Nerve cell death is the key event in all neurodegenerative disorders, with apoptosis and necrosis being central to both acute and
chronic degenerative processes. However, until now, it has not been possible to study these dynamically and in real time. In this
study, we use spectrally distinct, well-recognised ﬂuorescent cell death markers to enable the temporal resolution and
quantiﬁcation of the early and late phases of apoptosis and necrosis of single nerve cells in different disease models. The
tracking of single-cell death proﬁles in the same living eye over hours, days, weeks and months is a signiﬁcant advancement on
currently available techniques. We identiﬁed a numerical preponderance of late-phase versus early-phase apoptotic cells in
chronic models, reinforcing the commonalities between cellular mechanisms in different disease models. We showed that
MK801 effectively inhibited both apoptosis and necrosis, but our ﬁndings support the use of our technique to investigate more
speciﬁc anti-apoptotic and anti-necrotic strategies with well-deﬁned targets, with potentially greater clinical application. The
optical properties of the eye provide compelling opportunities for the quantitative monitoring of disease mechanisms and
dynamics in experimental neurodegeneration. Our ﬁndings also help to directly observe retinal nerve cell death in patients as
an adjunct to reﬁning diagnosis, tracking disease status and assessing therapeutic intervention.
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Cell death and neuronal loss are the key pathological drivers
of neurodegeneration in conditions such as Alzheimer’s
disease (AD), Parkinson’s disease, Huntington’s disease
and glaucoma, with increasingly recognised common
elements and triggers (e.g., oxidative stress, mitochondrial
dysfunction, excitotoxicity and misfolded protein aggregation)
and a convergence on downstream events.
1,2 For example,
the protein b-amyloid (Ab) seems to be involved in the eye in a
similar way asit is in the brain, with retinal Ab deposition being
strongly implicated in both AD and glaucoma.
3–6
Live cell imaging has been widely used to investigate
neuronal dysfunction in cultured cells in vitro, which, together
with ﬂuorescent multiple labelling, permits visualisation of
different cell activities and distinct molecular localisation
patterns. The use of annexin V and propidium iodide (PI) as
cell death markers has become an established method for
differentiating between the two major forms of cell death –
namely, apoptosis and necrosis. However, until now, inves-
tigationoftheprogressionanddynamicsofthedistinctphases
of neurodegenerative disease at the cellular level has
depended on histological or in vitro analyses.
7
Imaging the different phases of nerve cell death in vivo
would signiﬁcantly advance our ability to understand the
disease and its natural history, with direct applications to the
patient. It would allow an investigation into the time course of
events in relation to different modulators, and also provide
insight into the spatial patterns of cell death over periods of
days, weeks or longer. Furthermore, given the emergence of
mechanistic commonalities between different neurodegene-
rative diseases, such as AD and glaucoma,
5,6 an appreciation
of the spatio-temporal dynamics of cell death in one disease
could enhance our understanding of other diseases, in terms
of both the molecular pathophysiology and the potential
therapeutic avenues.
Compared with other mammalian organs, the eye offers
unique opportunities for imaging because the clear optical
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www.nature.com/cddismedia allow a direct visualisation of disease processes as
they occur. Recently, we described a technique for real-time
imaging of retinal ganglion cell (RGC) apoptosis in the
mammalian eye using confocal scanning laser ophthalmo-
scopy and ﬂuorescent-labelled annexin V.
1 In this study, we
used PI and 1,10-dioctadecyl-3,3,30,30-tetramethylindocarbo-
cyanine perchlorate (DiI) as additional cellular markers to
distinguish between early and late apoptotic and necrotic
phases of single nerve cell death in vivo. We carried this out in
established acute, chronic and treated models of neuro-
degeneration
1,6,8 to highlight the capabilities of snapshot and
longitudinal assessment. Changes in individual neurons were
visualised in the retina over hours, days and weeks, as were
the effects of modulating and neuroprotective agents, and
levels of cell death phase quantiﬁed.
In conclusion, our new technique shows the retina to be an
ideal experimental model that provides compelling opportu-
nities for the quantitative monitoring of disease mechanisms
and dynamics in experimental neurodegeneration. It also
helps to directly observe retinal nerve cell death in patients as
an adjunct to reﬁning diagnosis, tracking disease status and
assessing therapeutic intervention.
6,9
Results
Customising imaging equipment enables ﬂuorescent
triple-labelling detection. To simultaneously detect three
different ﬂuorochromes, we ﬁrst customised a prototype
Zeiss (Oberkochen, Germany) confocal scanning laser
ophthalmoscope (cSLO)
1 to enable the detection of
different emission wavelengths. The parameters used were
based on well-established ﬂuorescently tagged cell markers,
selected because of their distinct spectral properties and
minimal overlap, and the emitted light collection was
optimised with appropriate ﬁlters (Figure 1). For
identiﬁcation of apoptotic cells, we used Alexa Fluor 488-
labelled annexin V (Invitrogen, Paisley, UK), which has an
excitation and emission maxima of 495 and 519nm,
respectively, with an argon laser and a solid-state
photodetector with a 521nm cut-off ﬁlter and a 550nm
cut-on ﬁlter.
1 To identify necrotic and late-apoptotic RGCs, we
used PI with an excitation and emission maxima of 532 and
649nm, respectively, with detection using a diode-pumped
crystal green laser with a wavelength of 532nm and a 650nm
cut-off ﬁlter on the photodetector. After an empirical assessment
Figure 1 Confocal scanning laser ophthalmoscopy (cSLO) and detection of ﬂuorescent-labelled cells. Simultaneous detection of multiple markers was achieved by
customising the cSLO as follows: for identiﬁcation of annexin 488, an argon laser wavelength of 488nm and a solid-state photodetector with a 521nm cut-off ﬁlter and a
550nmcut-onﬁlterwereused;forDiI,adiode-pumpedcrystalgreenlaserwithawavelengthof532nmwasusedwith550nmcut-offand600nmcut-onﬁlters;thesamelaser
was used for PI visualisation but with a 650nm cut-off. The inset graph shows the emission spectra of cellular marker ﬂuorochromes used in this study. Alexa Fluor 488-
labelledannexinV(green;annexin488),DiI(blue;1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanineperchlorate)andpropidiumiodide(red;PI)haveexcitation/emission
maximaof495/519,550/570and532/649nm,respectively.(a–d)Monochromeimagesfromeachretinalareawereacquiredusingtheappropriatelasersetupandcolourised.
Three-colour images were produced by combining each of the grey scale images from the cLSO into the green (a, annexin 488), blue (b, DiI) and red channels (c, PI) of an
RGB colour image, and merged to form the image shown in (d) (scale bar 100mm)
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Cell Death and Diseaseof several different compounds, including DiAsp (4-(4-
(didecylamino)styryl)-N-methylpyridinium iodide (4-Di-10-Asp)),
Fluorogold and Rhodamine B, we determined that DiI was the
most suitable RGC marker in our rat models, with an excitation
and emission maxima of 550 and 570nm, respectively. The
same laser used for PI was used for DiI visualisation, but with
550nm cut-off and 600nm cut-on ﬁlters.
This system permitted multi-wavelength imaging with
high resolution and sensitivity, and minimal bleed-through
(Figure 1). Filters were speciﬁcally chosen for the ﬂuoro-
chromes used, but in principle, a diverse number of
ﬂuorescent markers used in a wide range of established cell
biology protocols could be studied with appropriate modiﬁca-
tion to the cSLO system – highlighting the use of the retina as
a model for studying in vivo cellular processes.
In vivo imaging allows longitudinal tracking of changes
in cell markers over time. Having deﬁned the functional
parameters of the technology, we next investigated its appli-
cation in vivo using animal models of neurodegeneration.
Staurosporine (SSP), a well-known non-selective protein
kinase inhibitor, is routinely used as a potent inducer of
neuronal apoptosis in in vitro assays.
10 We have previously
established that SSP may be conveniently used in vivo to
induce a rapid and fairly synchronous wave of RGC
apoptosis that is readily detected using annexin V.
1,11
Therefore, we ﬁrst studied the effects of SSP in rats in which
RGCs had been retrogradely labelled with DiI, followed by
intravitreal delivery of SSP, annexin V-488 and PI.
In this model, time-lapse video sequences (Figures 2a–e
and Supplementary Videos 1 and 2) of single retinal areas
over 5h revealed a random distribution and appearance of
apoptoticandnecroticcells,whichwasparticularlyhighlighted
by the 3D surface plot (Supplementary Video 2), and the
average intensity projections of the time-lapse sequence
shown in Figures 2f and g (generated by ImageJ RGB
Zprojector plugin). A graphical analysis of the image
sequencehistogramsdemonstratedthattheaverageintensity
proﬁles of annexin V and PI changed signiﬁcantly over time
(examples shown in Figure 2h).
These results demonstrate proof of principle that this
technique enables the tracking of changes in individual retinal
cells in the same eye over time, with the ability to temporally
and quantitatively analyse changes in ﬂuorescence intensity.
To our knowledge, this is the ﬁrst demonstration of the use of
high-resolution multi-wavelength imaging in visualising the
death of single neurons in vivo.
Identifying patterns of tracked single-cell death markers
over time in vivo. We next assessed whether the multi-
labelling of cells in vivo allowed the resolution of different
patterns of apoptotic and necrotic cell death. Owing to the
rapid kinetics and predominantly apoptotic mode of cell death
induced by SSP, we again investigated simultaneous triple
labelling in rats. Although the precise kinetics of the onset of
Figure 2 Time-lapse video analysis showing changes in cell markers in vivo.( a–g) Stills taken from video sequence (Supplementary Video 1) in an SSP-treated rat eye
withlabelledRGCs(DiI,blue)andintravitrealannexinV(green)andpropidiumiodide(PI,red)revealarandomdistributionandappearanceofannexinV-andPI-stainedcells,
but demonstrate the clear increase in PI staining over time. (DI, blue; annexin V, green; propidium iodide, red; time points and scale bar 100mm as indicated). (f, g) Average
ﬂuorescence intensityprojectionsof videosequencesusingImageJRGBZprojectorpluginwith annexin/PI(f)and allthreechannels(g).(h) Temporalanalysisof theaverage
annexin (green) and PI (red) intensities taken from each image sequence histogram demonstrates that the proﬁles of annexin and PI change signiﬁcantly over time, with a
marked increase in late PI staining
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Cell Death and Diseaseannexin-V positivity and the development of PI staining
varied from cell to cell, single-cell tracking allowed the
delineation of the natural history of the ﬂuorescence patterns.
In this SSP model,
1,9 single cells were identiﬁed from stills,
and a random sample (n¼30) was selected based on
whether they were DiI positive (i.e., white spots identifying
singleRGCs,Figure3a)andstainedwithannexinV-488,PIor
both. A video analysis of selected tracked individual cells
fulﬁlling these criteria (artiﬁcially labelled as light blue spots in
Figure 3b) using ImageJ software and the Time Series
Analyzer plugin allowed us to construct the intensity proﬁles
of annexin V and PI. From these proﬁles, it was found that
typicallythreepatternsofﬂuorescentlabellingwere observed,
as illustrated in Figure 3c, which is a colour map showing the
distribution of cells and their staining patterns. First, some
cellswerefoundtobelabelledonlywithPI(‘PIonly’,redspots,
Figure 3c), others were initially annexin V positive and
subsequently became PI positive (‘Annexin ﬁrst’, green spots,
Figure 3c), whereas others became positive for both dyes at
approximately the same time (‘similar proﬁles’, yellow spots,
Figure 3c). The patterns of ﬂuorescent labelling seemed to be
randomly distributed.
The tracking of annexin V-488 and PI staining in single cells
is clearly shown in the magniﬁed video stills illustrating
representative cells displaying speciﬁc patterns of ﬂuorescent
labelling (arrows in Figures 3e–g indicating ‘PI only’; i–k
Figure 3 Identiﬁcation of different patterns and phases of cell death in vivo.( a, b) Random sample (n¼30) of single cells selected according to whether they were DiI
positive (white spots, DiI retrogradely labelled retinal ganglion cells, a) and stained with annexin V-488, PI or both during time-lapse video (light blue spots, b). (c–p) Three
patternsofﬂuorescentlabellingwereidentiﬁed:‘PIonly’(redspots,(c),andtherepresentativecell,arrowedin(e–g)videostillswiththecorrespondingsignalintensityproﬁlein
(h)),‘Annexinﬁrst’(annexin-VpositiveandsubsequentlyPIpositive,greenspots(c,i–l)),‘similarproﬁles’(positivelabellingforbothdyesatthesametime,yellowspots,(c,m–p)).
The mean times to peak intensity (d) revealed that the appearance of the ‘PI only’ cells was signiﬁcantly quicker than either the ‘annexin ﬁrst’ or the ‘similar proﬁles’ cells.
Intensity proﬁles of annexin V and PI changed signiﬁcantly over time (h, l, p). These results provide evidencethat neuronal cells in vivo show considerable heterogeneity with
regard to the kinetics of necrotic and apoptotic cell death, and also the relative timing of phosphatidylserine exposure (early phase) and nuclear condensation (late phase).
Time points and scale bar 100mm as indicated
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Cell Death and Disease‘Annexinﬁrst’;andm–o‘similarproﬁles’),withthecorrespond-
ing graphs of signal intensity over time (Figure 3h, l and p). In
eachillustrativecase,theintensityproﬁlesofannexinVandPI
changed signiﬁcantly over time. The mean timings to peak
intensity of this random sample (Figure 3d) revealed that ‘PI
only’ cells tended to show signiﬁcantly shorter kinetics than
either the ‘Annexin ﬁrst’ or the ‘similar proﬁles’ cells. In
addition, cells that became annexin V positive invariably also
became PI positive, either within an hour or coincidentally.
These results provide evidence that neuronal cells in vivo
show considerable heterogeneity with regard to the kinetics of
necrotic and apoptotic cell death marker staining, and also, by
inference, the relative timing of phosphatidylserine exposure
(early-phase apoptosis) and nuclear condensation (late-
phase apoptosis).
Assessing the phases of cell death in vivo. In vitro FACS
analysis enables cells to be classiﬁed as being in early
apoptosis (annexin V positive only), necrosis (PI only) or
late-phase apoptosis (both annexin V and PI positive). To
quantify the magnitude of late-phase apoptosis in vivo,w e
studied individual levels of annexin V, PI and their co-
localisation using our recently developed Ab model of RGC
death.
6 The advantages of this methodology are well
established in the ﬁeld of cell biology, and provide a
snapshot of the status of RGC death at any one time. We
also evaluated the effects of treatment with the N-methyl-D-
aspartic acid (NMDA) channel blocker MK801, using the
same analytical methods.
Using the Ab model, we assessed the effects of intravitreal
Ab (Ab25 35), which was recently shown by us to induce RGC
apoptosis in rodent eyes.
6 Signiﬁcant RGC death occurred
72h after intravitreal administration of 3.40nmol Ab25 35 to
therighteye,a timethat,inpreviousstudies,was shownbyus
to yield peak levels of apoptosis (Figure 4). The left eye of
each animal was treated with intravitreal 0.40nmol MK801 at
the same time as Ab. Wide-angle retinal images were
recorded 2h after intravitreal annexin (green) and PI (red)
staining, as previously described. A typical image of an
Ab25 35-treated right eye (Figure 4a) compared with the left
MK801-treated eye of the same mouse (Figure 4b) demon-
stratesthatMK801treatmentreducesthenumbersofannexin
V (green)- and PI (red)-positive cells.
To assess the relative levels of early apoptosis, late
apoptosis and necrosis, we studied the co-localisation of PI
and annexin V using ImageJ software with the Intensity
Correlation Analysis plugin.
12 Colour and raw scatter plots of
annexin and PI ﬂuorescence intensity were constructed from
plugin-generated data for each animal. The corresponding
scatter plots (blue) from the eyes shown in Figures 4a and b
are illustrated in Figures 4c and d. Data were analysed in a
manner similar to that of data derived by in vitro FACS
analysis, with four quadrants (midlines shaded in colour
overlay as red, green, blue and yellow) enabling separation of
the different phases of cell death as annexin V positive (early
apoptosis, green), annexin V and PI double positive (late
apoptosis, yellow) and PI positive (necrosis, red). Thresholds
were set automatically by the plugin for the analysis of each
eye. We then used ﬂuorescence intensity counts from the raw
scatter plots to quantify each phase of cell death. MK801
treatment clearly reduced the overall levels of cell death
(total), but more particularly, the number of cells in late-phase
apoptosis and necrosis (Figure 4e). Interestingly, there was a
small increase in the number of early-phase apoptotic cells
(Anxþ) in MK801-treated eyes (Figure 4e). As these are
destined to become Anxþ/PIþ, this suggests that, although
the results generally support the neuroprotective role of
NMDA antagonists in Ab-induced neuronal cell death,
13 it
may be that the protective effects of MK801 seem transient
because of its single application in these experiments.
To further assess the analytical power of the technique, we
next investigated whether the level of oxidative stress in Ab-
treated eyes inﬂuenced the phase of cell death and whether
this was possible to be visualised in vivo. Live cell imaging of
glial/neuronal cultures has suggested that Ab increases
neuronal oxidative stress by activating NADPH oxidase in
microglia, an effect that is potentiated by phorbol myristate
acetate (PMA).
14 Figures 4f and g are taken from the right
untreated (f) and left PMA-treated (g) eye of an animal treated
72h previously with 3.40nmol Ab25 35. PMA (0.016nmol) or
vehicle was administered at the same time as intravitreal
annexin V and PI, with imaging performed 2h later. PMA
increased the numbers of annexin V (green)-positive cells
(Figures 4f and g), which was conﬁrmed by the co-localisation
scatter plots (Figures 4h and i). Quantiﬁcation of ﬂuorescence
in all animals revealed that PMA signiﬁcantly (Po0.05)
increased the overall levels of cell death in the Ab model, in
particular, the number of cells undergoing early-phase
apoptosis (Figure 4j). These results support the hypothesis
that PMA potentiates Ab-induced ROS damage via predomi-
nantly apoptotic pathways.
14
Using the same methodology, we next compared the
relative levels of cell death phases between the SSP and Ab
acute models of RGC death, at the time points at which we
previously showed peak RGC annexin V positivity to occur,
that is, at 2 and 72h, respectively.
1,6 Images were reanalysed
for all treated animals using co-localisation scatter plots and
the same methodology as described above. Figure 4k
illustrates that both SSP and Ab models exhibit similar
patterns of cell death at the time of peak apoptosis. The cell
death proﬁles in both models showed signiﬁcantly more cells
in the late phase of apoptosis (Po0.05) as opposed to
necrosis or early apoptosis.
The natural history of cell death in chronic glaucoma-
related models. Having demonstrated the application of this
technique in two acute models of RGC death, we next
investigated models of chronic retinal neurodegeneration,
which more closely resemble human disease. Our group has
previously characterised, using in vivo and histological
proﬁling of RGC apoptosis, an experimental glaucoma rat
model of ocular hypertension (OHT) caused by chronically
elevated intraocular pressure (IOP).
1,9 RGCs were retrogradely
labelled using previously described methods with DiI
1,6 and
animals were imaged repeatedly after administration of
intravitreal annexin V at different time points to generate
time-lapse video sequences (Figures 5a–f and
Supplementary Video 3). Assessment of intact labelled
RGCs in the glaucoma model (identiﬁed by DiI, blue,
Figure 5a) revealed dramatic changes in single RGCs. As
Imaging multiple phases of neurodegeneration
MF Cordeiro et al
5
Cell Death and Diseaseexpected, when compared with the number of cells identiﬁed
at baseline (Figure 5b) and at 3 weeks (Figure 5c), the
number of labelled RGCs evident at 8 weeks was markedly
reduced (Figure 5d) after surgical induction of elevated IOP.
Analysis of apoptosis induction in these retinas revealed
that those RGCs that were annexin V positive at
3 weeks (Figure 5e) disappeared by 8 weeks (Figure 5f),
suggesting that a wave of apoptosis follows the initial IOP
elevation insult, which is followed in turn by the clearance of
dead cells.
We next analysed the time sequence of annexin V and DiI
changes during this period. Using a method similar to that
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Cell Death and Diseasedescribed earlier for Figure 2, we constructed a maximum
intensity 3D projection of the time-lapse video sequences
(Supplementary Video 3), using the Image J RGB Zprojector
and JaCoP plugin. The projection enabled the quantitative
assessment of maximal annexin V and DiI staining at each
pixelinthesameretinalareastudiedovertime.Althoughthere
was a high overlap ratio of annexin V staining with DiI (0.63,
conﬁrming the presence of apoptosis at the level of the
RGCs), there was a very low ratio (0.072) of DiI cells also
positive for annexin V. This demonstrates either that only
some RGCs were ever annexin V positive and that apoptosis
isnottheonlypathwayresponsibleforcelldeathinthismodel,
or that annexin V positivity is transient (as shown in Figure 3).
We then investigated the presence of apoptotic and
necrotic cells using PI and annexin V. At 3 weeks, in the
OHT model, only a small proportion of RGCs was identiﬁed in
early apoptosis compared with late apoptosis, as seen in a
typical image in Figure 5g. Quantiﬁcation of cell death phases
was performed using the co-localisation scatter plots
described previously. There was a signiﬁcant (Po0.05)
increase in cells in late-phase apoptosis compared with either
necrosis or early-phase apoptosis (Figure 5i). Indeed, most
labelled cells were in late-phase apoptosis (Anxþ/PIþ), with
relativelyfewcellsexhibitingthediagnosticmarkersofnecrosis
(PIþ) or early-phase apoptosis (Anxþ). This distribution of
dyingcellsisbroadlysimilartothatseeninboththeSSPandAb
models (Figure 4k) at the time of peak apoptosis.
We next assessed whether neuroprotective treatment
altered the relative numbers of cells in each of the cell death
phases, using the NMDA antagonist MK801, which we have
previously shown to be effective in this model.
9 Treatment
with MK801 at the time of IOP elevation signiﬁcantly reduced
the numbers of both annexin V-and PI-positive cells
(Figure 5h). Co-localisation scatter plot analysis showed a
signiﬁcant reduction in total cell death markers (Po0.05), and
speciﬁcally a signiﬁcant reduction in both late-phase apoptosis
and necrosis, compared with untreated OHT eyes at 3 weeks
after elevated IOP induction.
Assessing phases of cell death in the Alzheimer triple
transgenic model. There is growing evidence of retinal
involvement in AD, with the demonstration using histological
techniques that RGC apoptosis occurs in double transgenic
AD models.
3,4 To determine whether phasing of RGC death
could be assessed in vivo in another model of chronic
neurodegeneration, we next applied our technique to a triple
transgenic AD model (3xTg-AD). This is an increasingly used
model of AD, which overexpresses APPSwe and tauP301L,
as well as carries a PS1M146V knock-in mutation, and is
currently the only existing transgenic model with both Ab and
tau neuropathology.
8 An accumulation of intraneuronal Ab
occurs early, which decreases as extracellular plaques are
deposited, similar to the development of disease and in
brains of patients with Down’s syndrome.
15
Previous transgenic studies
3,4 have shown that in the
double AD APP/PS1 mouse line, the level of RGC apoptosis
increasedwithage,beingmorepreponderantat27thanat7.8
months. However, inthesestudies aged (27-months old)wild-
type congeners were not assessed. Figure 6a demonstrates
the typical appearance of the eye of a 14-month-old 3xTg-AD
model imaged at 2h after intravitreal PI and annexin-IR
treatment alongside the similarly imaged eye of an 18-month-
old control (PS1KI transgenic mouse that shows no Ab and
tau neuropathology
16) (Figure 6b). To quantify the levels of
the different phases of cell death, we again used data
generated from co-localisation scatter plot analysis, which
showed signiﬁcantly more RGCs in the phase of early
apoptosis (Po0.05, green, Anxþ) and less necrosis
(Po0.05, red, PIþ) in 3xTg-AD compared with aged control
(Figure 6c). These data show that, although a low level of
apoptotic and necrotic cell death occurs as a correlate of
normal healthy ageing in mice, in AD mice, there is a
signiﬁcant increase in the relative numbers of RGCs in
early-phase apoptosis.
We next investigated whether oxidative stress in AD eyes
inﬂuenced the phase of cell death and whether this could be
visualised in vivo. As intraneuronal Ab accumulation and
extracellular Ab plaquesare the characteristics of thismodel,
15
wehypothesisedthattheadditionofPMAwouldrevealwhether
thelevelofAbinthistransgenicmouseissufﬁcienttomodulate
the retinal response in vivo.
14 We therefore compared the
effects of PMA in 14-month-old 3xTg-AD animals (Figure 6d)
andcontrolagedanimals(Figure6e).PMAseemedtoincrease
thelevelofannexinstaininginthetreatedeyesofbothanimals.
However, quantiﬁcation revealed that although PMA treatment
signiﬁcantly increased early-phase apoptosis in both control
and 3xTg-AD eyes (Po0.05, Figures 6f and g), the magnitude
of the increase was far less in control eyes than in 3xTg-AD
(30.3% in aged control, 61.4% in 3xTg-AD). PMA also
decreased late apoptosis (Po0.05) in the 3xTg-AD model
and necrosis (Po0.05) in control eyes.
These ﬁndings show that PMA stimulates a higher rate of
early-phase apoptosis (annexin V staining alone) in 3xTg-AD
animals, and are consistent with the data in Figure 4 showing
a similar effect of PMA in the model of acute RGC death
mediated by Ab.
Figure 4 Analysis of cell death phases in a mouse model of Ab-induced RGC death. (a, b) Wide-angle retinal images showing the Ab-treated right eye (a) and
AbþMK801-treated left eye (b) of a single mouse. MK801 reduces the number of annexin V (green)- and PI (red)-positive cells 72h after intravitreal Ab(25–35) application.
To assess the magnitude of late apoptosis, we studied the co-localisation of PI and annexin V using ImageJ software with the Intensity Correlation Analysis plugin.
12 (c, d)
Scatter plots show the distribution of annexin and PI ﬂuorescence intensity in the eyes shown in (a, b), Ab alone (c) and AbþMK801 (d). (e) Thresholds were set
automatically by the plugin for each analysis (colour overlay in (c, d)), and quantiﬁcation of each cell death phase was performed from generated data (e). MK801 treatment
reducedtheoveralllevelsofcelldeath(blue,total),mostlybyreducingthenumberofcellsinlate-phaseapoptosis(yellow,Anxþ/PIþ)andnecrosis(red,PIþ).(f,g)Wide-
angleretinalimagesshowingtheAb-treatedrighteye(f)andAbþPMA-treatedlefteye(g)ofasinglemouse.(h,i)PMAincreasedthelevelofannexinV(green)andPI(red)
positivity,as shown in the corresponding scatter plots. (j) Quantiﬁcationof all treatedanimals shows that PMA signiﬁcantly (Po0.05) increases the overall levels of cell death
(blue,total),mostofthisbeingduetoasigniﬁcant(Po0.05)increaseinthenumberofcellsintheearlyphaseofapoptosis(green,Anxþ).(k)Comparisonofcellphasesinall
AbandSSPmodelsusingco-localisationscatterplotanalysis.Atthepreviouslyestablishedtimepointsofmaximalapoptosis(Ab¼72handSSP¼2h),bothmodelsshowa
similar trend, with no signiﬁcant difference in the magnitude of any phase of cell death. However, both models show signiﬁcantly more RGCs in the phases of late apoptosis
(P40.05, yellow, Anxþ/PIþ) and necrosis (P40.05, red, PIþ) than early apoptosis (green, Anxþ). Error bars 95% conﬁdence intervals, *Po0.05
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Cell Death and DiseaseDiscussion
Neuronal cell loss is the key functional event in all
neurodegenerative disorders, with apoptosis and necrosis
being central to both acute and chronic degenerative
processes.
17 We report here, for the ﬁrst time in vivo,a
technique that enables temporal resolution and quantiﬁcation
of the early and late phases of apoptosis and necrosis of
single nerve cells using different models of disease.
The methodology permits the tracking of changes in the
same cell in the same eye over hours, days, weeks and
monthsinacute,chronicandtreatedglaucomaandAlzheimer
Figure5 Naturalhistoryofcelldeathinachronicocularhypertensive(OHT)modelofneurodegeneration.(a–f)CellswereretrogradelylabelledusingDiI(a),andanalysed
at intervals over 8 weeks. The higher magniﬁcation image (green box in (a)) taken at time zero (b) shows the normal density of RGCs, with little change at 3 weeks (c).
However, there was marked RGC dropout 8 weeks after surgical induction of elevated IOP (d). When the data were analysed with respect to the identiﬁcation of apoptosis in
thesesamecells,itwasclearthatthoseRGCsthatwereannexinVpositiveat3weeks(e)werenolongeridentiﬁableat8weeks(f),conﬁrmingthatcellsoriginallyclassiﬁedas
undergoing apoptosis degenerated 5 weeks later. (g) Only a small proportion of RGCs was identiﬁed in early-phase apoptosis (annexin V only) compared with late-phase
apoptosis (both annexin V and PI staining) at 3 weeks. (h) MK801 treatment of animals at the time of surgery signiﬁcantly reduced the number of both apoptotic and necrotic
cells 3 weeks after treatment. (i) Quantitative analysis of the co-localisation data for PI and annexin V conﬁrmed that signiﬁcantly more cells were in late-phase apoptosis
(P40.05,yellow,Anxþ/PIþ)thaninnecrosis(red,PIþ).TreatmentwithMK801ledtoasigniﬁcantreduction(Po0.05)inthenumberofdyingcells(total),mostlybecause
ofasigniﬁcantdecreaseinthelevelsofnecrosis(P40.05,red,PIþ)andlateapoptotic(P40.05,yellow,Anxþ/PIþ)celldeath.Scalebar100mmasindicated,errorbars
represent 95% conﬁdence intervals, *Po0.05
Imaging multiple phases of neurodegeneration
MF Cordeiro et al
8
Cell Death and Diseasemodels of neurodegeneration. It has enabled us to identify a
numerical preponderance of late-phase versus early-phase
apoptotic cells in vivo, and reinforced the commonalities
betweendisease mechanisms in the different models studied.
The predominance of late-phase apoptosis may reﬂect not
only the relatively short duration of the early phase compared
with the late phase (previously estimated as within 1hour
ex vivo,
18 and suggesting that the relative likelihood of
detecting cells in early apoptosis is low at any given time
19)
but also, as we show here (‘similar proﬁles’ in Figure 3), the
coincidental appearance of annexin V and PI positivity in
many apoptotic cells.
The shared characteristics of cell death patterns in different
disease models is an important aspect of the technique
presented here, with particular relevance to the design of
more effective and targeted therapeutics. NMDA antagonists
have long been advocated in neuroprotective strategies
20,21
in both AD
22 and glaucoma,
9,21 and MK801 effectively
inhibited both apoptosis and necrosis in our different models,
consistent withtheroleof Ca
2þ inmediatingboth formsofcell
death. However, these ﬁndings support the use of our
technique to investigate more speciﬁc anti-apoptotic and
anti-necrotic strategies with well-deﬁned targets, with poten-
tiallygreaterclinicalapplication.Itmaybethattheuseofthese
strategies will depend on the stage of the disease in the
patient, which may eventually be deﬁned by an apoptotic/
necrotic index, a ratio that may indicate disease severity and
progression.
A major advantage of our approach is that it allows a
temporal delineation of the natural history of neuronal loss.
Various attempts to discriminate between the various modes
of cell death in neurodegenerative diseases such as AD have
Figure 6 Retinal cell death in the Alzheimer Triple Transgenic model. (a, b) Representative wide-angle retinal images of a 14-month-old Alzheimer Triple Transgenic
(3xTg-AD, a) mouse acquired 2h after intravitreal PI (red) and annexin (green), compared with (b) an 18-month-old PS1KI control mouse. (c) Quantitation of co-localisation
scatterplotdatashowingsigniﬁcantlymoreRGCsintheearlyphaseofapoptosis(Po0.05,green,Anxþ)andrelativelyfewernecroticcells(Po0.05,red,PIþ)inthe3xTg-
AD model compared with control. (d, e) Retinal images of the eyes of a 14-month-old 3xTg-AD animal (d) and a control aged animal (e) acquired 2h after PMA was
administered at the same time as intravitreal annexin (green) and PI (red). (f, g) Quantiﬁcation of the data generated by co-localisation scatter plot analysis showed that PMA
treatmentsigniﬁcantlyincreasedearly apoptosis(Po0.05,green,Anxþ)anddecreasedlate apoptosis(Po0.05,yellow,Anxþ/PIþ)in the3xTg-ADmodel(g).PMA also
increasedthelevelof earlyapoptosisinaged controlanimals(Po0.05,green, Anxþ), althoughnottothesameextent (30.3%inaged controlasopposedto 61.4%in3xTg-
AD). *Po0.05
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Cell Death and Diseasebeen inconclusive, with mixed features of apoptosis, necrosis
andautophagybeingdetectedthroughavarietyofhistological
andbiochemicalstrategies,whicharedifﬁculttoextrapolateto
the dynamic events that occur in vivo.
23 The overlap between
apoptosis and necrosis pathways has been linked to insult
exposure,
24 with necrosis being associated with excessive
pathological neuronal loss,
25 now considered to be the
‘default’ cell death pathway when apoptotic cell death is
inhibited.
26 Further investigation to elucidate whether the
mode of neurodegenerative cell death is directly determined
by the strength of the cell death stimulus is needed.
On the whole, most glaucoma studies have focused on the
development of generic RGC loss rather than on the speciﬁc
mode of cell death, although some have proposed apoptosis
as the predominant pathway.
27–29 Our results lead us to
suggest that, although apoptosis may be involved in the
primary phase of degeneration in animal models, necrosis
is probably the major cell death pathway in secondary
degeneration
30 in glaucoma. It will be interesting to use the
imaging technique developed in this study, in combination
with the many ﬂuorescent cell-permeant probes available for
caspase activation, Ca
2þ ﬂuxes, mitochondrial function and
so on, to examine degeneration phases in other transgenic
neurodegeneration models, as the balance between apopto-
sis and necrosis is still unclear in chronic disease. Further-
more, delineation of the timing of such events and their
association with RGC apoptosis will highlight processes that
precede the irreversible stages of cellular degeneration, and
provide improved and speciﬁc targets for neuroprotection.
Annexin 5 is already used systemically and safely in
patients,
31,32 and there are a number of necrosis markers
that are already being used in clinical trials, such as 99mTc-
pyrophosphate, 111In-antimyosin and 99mTc-glucarate.
32
Hence, although it is unlikely that PI can be used in patients,
there are alternative agents that are potentially available to
allow this methodology to be translated directly to the clinic.
The ability to differentiate between apoptosis and necrosis
and non-invasively track cell death in neurodegenerative
pathologies could have an important role in medical diag-
nostics and therapy management. Furthermore, we believe
that the concept of an early apoptotis/necrosis ratio with a
correlation to disease activity may provide an invaluable tool
for staging neurodegeneration. There is increasing evidence
of the potential reversibility of early apoptosis, suggesting that
a high early apoptosis/necrosis ratio may offer a good
prognosis for treatment.
33,34
In conclusion, the application of this new technology has
far-reaching implications for studying intracellular processes
at the single-cell level in vivo. Although the equipment we use
in these studies has been customised to suit animal models,
the instruments are essentially the same as those used in
hospitals and clinics around the world. This raises the
possibility that in the near future, clinicians may be able to
assess retinal nerve cell death in vivo as a method of
monitoring disease progression and treatment efﬁcacy.
Whether a single snapshot or long-term in vivo observation
over many weeks is needed, the ability to visualise and track
changes in cell viability offers the potential for major advances
in the diagnosis and management of neurodegenerative
diseases.
Materials and Methods
Animal models. For our investigations in rats, we used established models of
retinal neuronal apoptosis.
1 All procedures complied with local and national
regulations and were performed under general anaesthesia. Adult dark Agouti (DA)
rats, 150–200g, were used in all rat experiments.
For the experimental glaucoma studies, we used an established model of ocular
hypertension. Eighteen rats were operated to elevate their IOP by injection of
hypertonic saline solution (1.8M) into episcleral veins as previously described.
1
Contralateral,unoperatedeyeswereusedascontrols.Animalswereimagedat0,3,
8 and 16 weeks, with at least three animals at each time point being killed for
histological analysis immediately after imaging. A subgroup of animals (n¼4) was
treated at the time of surgery with the NMDA antagonist MK801 (0.6nmol; Tocris
Cookson, Bristol, UK). These animals were imaged at 3 weeks and then killed for
histology.
For analysis of SSP-induced RGC apoptosis, 14 DA rats were given 0.5mgo f
intravitreal SSP in 5ml phosphate-buffered saline (PBS), both from Sigma-Aldrich
(Dorset, UK), to induce RGC apoptosis as previously described.
1 Animals were
imaged immediately for up to 6h, after which they were killed for histology.
For the analysis of Ab, freshly prepared Ab25 35 (Sigma-Aldrich, 3.40nmol)
35
was intravitreally injected into C57 mice (n¼10).
11 The animals were imaged at
72h.ForAD3xTg-ADstudies,foureyes(allfemale,14months),withtwoeyesfrom
aged control mice (PS1KI; female, 18 months), were assessed. 3xTg-AD and
control PS1KI mice were obtained from a colony (maintained at CeSI) established
aftertheywerereceivedasagenerousgiftfromFrankLaferla.IntravitrealPMA(1ml
of10mg/ml)wasadministeredtothelefteyesof3xTg-ADanimals,atthesametime
as annexin V and PI.
Fluorescent in vivo labelling. To identify RGC, retinas were retrogradely
labelled using different agents in pilot studies by their application to both superior
colliculi, as previously described.
1 Pilot studies identiﬁed DiI (10% solution;
Molecular Probes, Cambridge Biosciences, Cambridge, UK) as being better than
DiAsp(4-Di-10-Asp,FluorogoldorRhodamineB).DiIwasapplied10daysbeforeall
the rat treatment procedures detailed above. DiI is a long-chain dialkylcarbocyanine
lipophilic neuronal tracer, which does not affect cell viability, development or the
basic cellular physiological properties.
36
Using a method that we recently described, rats were administered 2.5mgo f
intravitreal Alexa Fluor 488-labelled annexin V in 5ml PBS for identiﬁcation of RGC
apoptosis, 2h before in vivo imaging.
1 For mice, we used 1ml of a 0.25mg/ml
solution of IR-labelled annexin (Annexin-IR) through intravitreal injections as
previously described.
37
To identify necrotic RGCs in rats (2ml) and mice (1ml), PI (0.4mg/ml, 1%
solution, Sigma-Aldrich) was administered intravitreally at the same time as
annexin, 2h before in vivo imaging. PI intercalates into nucleic acids, binding to
double-stranded DNA, but only crosses the plasma membrane of non-viable cells.
Cells that have lost membrane integrity are thus identiﬁed by ﬂuorescent red PI
staining throughout the nuclei.
Imaging. All rats had in vivo retinal imaging performed at regular and set
intervals after experimental treatment using a prototype Zeiss cSLO, as previously
described.
1,11 Imaging was performed under general anaesthesia with animals
being heldin a stereotaxicframe, with their pupils dilated. Differentlasers and ﬁlters
were used for different ﬂuorochromes: for excitation of Alexa Fluor 488, an argon
laser wavelength of 488nm and a solid state photodetector with a 521nm cut-off
ﬁlter and a 550nm cut-on ﬁlter were used; for DiI, a diode-pumped crystal green
laser with a wavelength of 532nm was used with 550nm cut-off and 600nm cut-on
ﬁlters; the same laser was used for PI visualisation, but with a 650nm cut-off. The
cSLO usedin this study is the same as that describedpreviously, with modiﬁcations
complyingwiththeestablishedstandardsfor safetyandlightexposure.
1,37Wehave
developed a purpose-written software to allow optimal processing of low-light
ﬂuorescent signals, which has greatly aided our live cell imaging.
1 Monochrome
images from each area were acquired using the appropriate laser setup and
colourised. Three-colour images were produced by combining each of the grey
scale images from the cSLO into the red (PI), green (annexin 488) and blue
channels(DiI)ofanRGBcolourimage.Imageswereprocessedinthiswaybecause
red,green and blue(RGB) colours are universallyaccepted as the most informative
methods for showing co-localisation. The ImageJ Intensity Correlation Analysis
plugin was applied to generate co-localisation scatter plots and colour thresholds.
12
Colour and raw scatter plots of annexin and PI ﬂuorescence intensity were
constructed; hence, the data could be analysed in a similar manner to that of the
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Cell Death and Diseasedata derived by in vitro FACS analysis. Separation of the different phases of cell
death according to whether they were annexin V positive (early apoptosis), annexin
V and PI double positive (late apoptosis) or PI positive (necrosis) was enabled by
the adoption of thresholds set automatically by the plugin for each analysis.
Fluorescence intensity counts derived from raw scatter plots were used to quantify
each phase of cell death.
In mice, we used instrumentation as previously described,
11,37 with a modiﬁed
cSLO (Heidelberg Retina Angiograph 2, Heidelberg Engineering, Dossenheim,
Germany) and a wide-ﬁeld lens (551). The ﬂuorescein angiogram (488nm argon
laser) and indocyanine green (IR 790nm diode laser) settings were used to detect
PI- and IR-labelled annexin, respectively. The same software was used to analyse
video-sequenced images as described before, with whole retinal monochrome
images of each eye recorded and colourised. Dual-color images were produced by
combining each of the grey scale images from the cSLO into the red (PI) and green
(IR annexin) channels of an RGB colour image.
Analysis. ImageJ software was used with speciﬁc plugins to create 3D surface
plots, RGB projections and to analyse co-localisation (JaCoP and Intensity
Correlation Analysis). Graphical data for mean values were contrived with 95%
conﬁdence intervals, and comparisons across groups were performed using
ANOVA or Student’s t-test for paired eyes, with Po0.05 as the signiﬁcance level.
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